Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2655${count})

  • Therapeutic Pipeline Program, 2023
    Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease

    Study Rationale: Our project will test the effectiveness of a new treatment for Parkinson’s disease (PD). Developed by Sanofi, the drug — called Tolebrutinib — blocks inflammation in the brain. Based...

  • Research Grant, 2023
    Exploiting a Novel Mechanism for Gene Regulation to Develop Innovative, Targeted Therapies for Parkinson’s Disease

    Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are associated with a variety of disease-causing mutations and genetic variants. In addition...

  • Translational Pipeline Program, 2023
    Development of a Small Interfering RNA that Reduces Production of Alpha-synuclein in Parkinson's Disease

    Study Rationale: Parkinson’s disease (PD) is associated with a buildup of alpha-synuclein aggregates in the brain. Modulation of alpha-synuclein accumulation has been shown in multiple preclinical...

  • Research Grant, 2022
    Examining the Role of Cannabinoid Receptor 2 in Inflammatory Responses Triggered by Alpha-synuclein

    Study Rationale: There is growing interest in the anti-inflammatory properties of cannabis-related compounds as a potential therapy for Parkinson’s disease (PD). Cannabis acts on cannabinoid receptors...

  • Research Grant, 2022
    Development of a Radiolabeled Tracer for Detecting Insoluble Protein Aggregates in Parkinson’s Disease

    Study Rationale: Many neurodegenerative disorders are caused by a toxic buildup of insoluble protein aggregates.  In Parkinson’s disease (PD), accumulation of alpha-synuclein contributes to the death...

  • Expanding Biological Understanding of Parkinson's Disease, 2022
    Deep Phenotyping of Parkinson's Disease Relevant Mitochondrial and Autophagic Mechanisms in Human iPSC-derived Neural Cells

    Study Rationale: The causes of Parkinson’s disease (PD) are not fully understood. However, impairment in the function of mitochondria, the powerhouses of the cell, and in autophagy, a process whereby...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.